Isabl LinkedIn · Jan 2026
Isabl announced the pan-cancer study collaboration with Weill Cornell Medicine and emphasized that its WGS-based HRD classifier found HRD phenotypes beyond BRCA1/2 mutations.
Cancer tests based on whole genome and transcriptome data.
Company research
Public company, workplace, funding, and market signals
Overview
Isabl is a New York-based oncology diagnostics company building a whole-genome-and-transcriptome sequencing SaaS platform for cancer testing and biomarker discovery.
Primary product
Isabl GxT / WGTS SaaS platform
Founded
2020
Headquarters
New York, New York, United States
Team size
1-10
Work style
Remote
Industry
Medical and Diagnostic Laboratories
Sub-industry
oncology diagnostics / cancer genomics / molecular diagnostics
Offices
175 Greenwich Street, Floor 38, Manhattan, NY 10007
3 World Trade Center, New York, NY 10007 (HQ)
Business model
SaaS
clinical diagnostics
commercial licensing
academic/research use (free)
Funding
Stage
seed
Total raised
$5.1M
Latest round
Grant · Apr 2023
Latest amount
$2M
People & investors
Leadership
CEO and Scientific Co-founder
CTO and Technical Co-founder
Medical Co-founder
VP, Business Operations
Chief Bioinformatics Officer
Chief Business Officer (acting)
Work & culture
Mission-driven and patient-focused, with a remote-first operating style, collaboration across science and engineering, and explicit values around focus, nimbleness, innovation, reliability, tenacity, and integrity.
Work style
Remote
Compensation
No public salary bands were found; public hiring signals mention equity as a benefit, but no detailed compensation ranges were disclosed.
Benefits
equity
remote-first
NYC office access
unlimited coffee
mission-driven work in cancer diagnostics
Product & market
Pricing
Free for academic and research use; commercial use requires a license; ACH payments are accepted.
Differentiators
- —Whole-genome plus transcriptome analysis instead of panel-based testing
- —Clinically actionable reporting in hours to about a day
- —FDA Breakthrough Device Designation
- —Integrated data platform spanning database, API, CLI, and web app
- —Proprietary WGS-based HRD classifier
- —Built for reproducible, FAIR, multimodal patient-centric workflows
Technology
Python
Django
PostgreSQL
Redis
Gunicorn
Celery
Docker Compose
Caddy
OpenAPI
Swagger
Redoc
AWS S3
Isabl-db
Isabl-api
Isabl-cli
Isabl-web
Customers
Memorial Sloan Kettering Cancer Center (Department of Pediatrics)
Memorial Sloan Kettering Cancer Center (Microbiome Program)
Memorial Sloan Kettering Cancer Center (Single-Cell Analytics Service / SAIL)
Sohrab Shah's lab
Cristina Curtis Lab at Stanford Medicine
Weill Cornell Medicine
Competitors
Caris Life Sciences
Personalis
Geneoscopy
Inocras
4baseCare
Foundation Medicine
Scale & contact
Estimated revenue
~$5M estimated ARR (third-party 2024 estimate)
Latest news
GenomeWeb · Jan 2026
GenomeWeb covered the Communications Medicine paper showing Isabl's WGS-based HRD classifier can detect homologous recombination deficiency missed by commercial assays.
Weill Cornell Medicine Newsroom · Jan 2026
Weill Cornell highlighted a study using Isabl-developed whole-genome sequencing analysis to improve identification of patients who may benefit from PARP inhibitors, citing better performance than current commercial methods.
Communications Medicine / Nature · Jan 2026
Peer-reviewed publication describing the Isabl HRD classifier and its evaluation across a pan-cancer cohort, including validation against commercial HRD tests.
TechCrunch · May 2022
TechCrunch covered Isabl coming out of stealth, FDA Breakthrough Device Designation, and its $3M seed round led by Two Sigma Ventures.
Jobs and careers at Isabl
0 jobs at Isabl
No open positions
Check back later for new openings